Ligand Pharmaceuticals Incorporated | Uncategorized | Business Contracts

Tax Matters Agreement, dated as of November 1, 2022, by and among Ligand Pharmaceuticals Incorporated, OmniAb Operations, Inc. and OmniAb, Inc (Filed With SEC on November 4, 2022)

Sublicense Agreement between the Company, Pharmacopeia, Inc. and Retrophin LLC dated as of February 16, 2012, as amended through Amendment No. 5 to Sublicense Agreement, dated... (Filed With SEC on February 28, 2022)

Description of Registered Securities (Filed With SEC on February 24, 2021)

Call Option Amendment Agreed, dated January 28, 2021, between the Registrant and Barclays Bank PLC (Filed With SEC on February 24, 2021)

Call Option Amendment Agreed, dated January 28, 2021, between the Registrant and Deutsche Bank AG, London Branch (Filed With SEC on February 24, 2021)

Call Option Amendment Agreed, dated January 28, 2021, between the Registrant and Goldman Sachs & Co. LLC (Filed With SEC on February 24, 2021)

Contingent Value Rights Agreement between Ligand Pharmaceuticals Incorporated and Vaughn Smider, as Members Representative (regarding Taurus Biosciences, LLC acquisition), dated... (Filed With SEC on September 10, 2020)

Asset Purchase Agreement, dated February 11, 2020, (as amended on April 1, 2020), by and among the Registrant, Icagen Inc., Icagen Corp., XRPro Sciences, Inc. and Caldera... (Filed With SEC on May 8, 2020)

Call Option Amendment Agreed, dated April 6, 2020, between the Registrant and Barclays Bank PLC (Filed With SEC on May 8, 2020)

Call Option Amendment Agreed, dated April 6, 2020, between the Registrant and Deutsche Bank AG, London Branch (Filed With SEC on May 8, 2020)

Call Option Amendment Agreed, dated April 6, 2020, between the Registrant and Goldman Sachs & Co. LLC (Filed With SEC on May 8, 2020)

Description of Registered Securities (Filed With SEC on February 27, 2020)

Sublicense Agreement between the Company, Pharmacopeia, Inc. and Retrophin LLC dated as of February 16, 2012, as amended through Amendment No. 5 to Sublicense Agreement, dated... (Filed With SEC on February 27, 2020)

Rule 2.7 Announcement issued by Ligand Holdings UK Ltd., dated August 9, 2018 (Filed With SEC on August 9, 2018)

Cooperation Agreement, dated August 9, 2018, by and between Vernalis plc and Ligand Holdings UK Ltd (Filed With SEC on August 9, 2018)

Break Fee Agreement, dated August 9, 2018, by and between Vernalis plc and Ligand Holdings UK Ltd (Filed With SEC on August 9, 2018)

Supplemental Indenture, dated as of February 20, 2018, between the Company and Wilmington Trust, National Association, as trustee (Filed With SEC on July 30, 2018)

LIGAND PHARMACEUTICALS INCORPORATED AND WILMINGTON TRUST, NATIONAL ASSOCIATION, as Trustee INDENTURE Dated as of May 22, 2018 0.75% Convertible Senior Notes due 2023 TABLE OF... (Filed With SEC on May 22, 2018)

Letter Agreement, dated as of May 17, 2018, between Barclays Capital Inc. and the Company regarding the Base Convertible Note Hedge Transaction (Filed With SEC on May 22, 2018)

Letter Agreement, dated as of May 17, 2018, between Barclays Capital Inc. and the Company regarding the Base Warrant Transaction (Filed With SEC on May 22, 2018)

Letter Agreement, dated as of May 17, 2018, between Deutsche Bank AG and the Company regarding the Base Convertible Note Hedge Transaction (Filed With SEC on May 22, 2018)

Letter Agreement, dated as of May 17, 2018, between Deutsche Bank AG and the Company regarding the Base Warrant Transaction (Filed With SEC on May 22, 2018)

[Signature Page Follows] (Filed With SEC on May 22, 2018)

Letter Agreement, dated as of May 18, 2018, between Barclays Capital Inc. and the Company regarding the Additional Convertible Note Hedge Transaction (Filed With SEC on May 22, 2018)

Letter Agreement, dated as of May 18, 2018, between Barclays Capital Inc. and the Company regarding the Additional Warrant Transaction (Filed With SEC on May 22, 2018)

Letter Agreement, dated as of May 18, 2018, between Deutsche Bank AG and the Company regarding the Additional Convertible Note Hedge Transaction (Filed With SEC on May 22, 2018)

Letter Agreement, dated as of May 18, 2018, between Deutsche Bank AG and the Company regarding the Additional Warrant Transaction (Filed With SEC on May 22, 2018)

Letter Agreement, dated as of May 18, 2018, between Goldman Sachs & Co. LLC and the Company regarding the Additional Warrant Transaction (Filed With SEC on May 22, 2018)

Amendment No. 5 to Sublicense Agreement, dated March 20, 2018, among the Company, Pharmacopeia, LLC and Retrophin, Inc (Filed With SEC on May 9, 2018)

License Agreement, dated March 5, 2018, by and between the Company and Roivant Sciences GmbH (Filed With SEC on May 9, 2018)

Agreement and Plan of Merger, dated as of October 4, 2017, by and among Ligand Pharmaceuticals Incorporated, Eagle Acquisition, Inc., Crystal Bioscience, Inc. and Shareholder... (Filed With SEC on October 4, 2017)

Third Amendment to Loan and Security Agreement (Filed With SEC on May 9, 2017)

LIGAND PHARMACEUTICALS INCORPORATED DIRECTOR COMPENSATION AND STOCK OWNERSHIP POLICY (Amended and Restated Effective March [ ], 2014) I. DIRECTOR COMPENSATION (Filed With SEC on November 14, 2016)

SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT (Filed With SEC on May 9, 2016)

CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY... (Filed With SEC on May 9, 2016)

Consent of Independent Registered Public Accounting Firm (Filed With SEC on March 22, 2016)

AGREEMENT AND PLAN OF MERGER BY AND AMONG LIGAND PHARMACEUTICALS INCORPORATED, SCHRADER 1 ACQUISITION, INC., SCHRADER 2 ACQUISITION, INC., OPEN MONOCLONAL TECHNOLOGY, INC., OMT,... (Filed With SEC on December 18, 2015)

LEASE 3911/3931 SVB,LLC, a California limited liability company as Landlord, and LIGAND PHARMACEUTICALS INCORPORATED, a Delaware corporation, as Tenant. 3911Sorrento Valley... (Filed With SEC on November 10, 2015)

AMENDMENT NO. 4 TO SUBLICENSE AGREEMENT (Filed With SEC on November 9, 2015)

SECOND AMENDMENT TO MASTER LICENSE AGREEMENT (Filed With SEC on August 5, 2015)

Ligand Pharmaceuticals Incorporated (208) | Uncategorized (184)